Advances in targeting KRAS mutations: A promising approach for the treatment of non‑small cell lung cancer (Review).

Oncol Rep · 2026 · PMC12805455 · PMID 41508946

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

By contrast, TP53 co-mutations were associated with a shorter OS (19.1 months), although the analysis did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.